Global liver fibrosis treatment market size is expected to witness a CAGR of 10.8% over the forecast period (2018 – 2026) reaching a value of US$ 28.1 billion in 2026.

Overview

Liver fibrosis is a condition in which the liver is repeatedly or continuously damaged, leading to an abnormally vast volume of scar tissue. Fibrosis has no symptoms, but extensive scarring leads to cirrhosis, which causes symptoms. Healthcare providers use blood and imaging tests to determine the severity of the condition, which may be followed by a liver biopsy if necessary. Healthcare specialists focus on addressing the source of liver fibrosis, which typically stops and slows future scarring of the liver and resulting in a recovery of the condition. Antibiotics, removing or dissolving an obstruction in the bile ducts, lifestyle changes such as reducing alcohol consumption, regulating prevalence of obesity, and managing blood sugar and glucose profiles in people with nonalcoholic fatty liver are all possible effective treatments for liver fibrosis.

Get Sample Report Of Liver Fibrosis Treatment

Drivers

Moreover, many private research organizations are projected to support research related to the development of treatments for liver fibrosis and other fatty liver diseases, which is projected to boost growth of the global liver fibrosis treatment market. Professors from Virginia Tech’s College of Science and the University of Virginia’s Department of Pharmacology won a $400,000 grant from the VBHRC (Virginia Biosciences Health Research Corporation) in August 2018, with $800,000 in matching funding from Continuum Biosciences, Inc. Researchers will be able to develop medications to treat nonalcoholic steatohepatitis with the support of this funding and matching money.

Browse 24 Market Data Tables and 28 Figures spread through 168 Pages and in-depth TOC on ‘Liver Fibrosis Treatment Market, by End User (Specialty Clinics, Hospitals, and Others), by Treatment Type (Hepatotropic Drug, PPAR (Peroxisome Proliferator-activated Receptors) alpha agonist, and ACE Inhibitors), by Region (North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa), and by Condition (Nonalcoholic Steatohepatitis, Chronic Liver Diseases, and Hepatitis C) – Global Forecast to 2026’

In addition, rising research partnership among major companies to create innovative treatment regimes, as well as regulatory approval of new medications for the treatment of liver fibrosis, are projected to fuel the global liver fibrosis treatment market expansion in the near future. Nordic Bioscience and Bristol-Myers Squibb Company inked a partnership agreement in April 2017 to develop biomarker technologies that might be used to track and measure fibrosis diseases such as non-alcoholic steatohepatitis (NASH). This partnership will aid patients in diagnosing and monitoring their fibrosis. SYMDEKO was authorized by the Food and Drug Administration (FDA) in February 2018 for the therapy of CF (cystic fibrosis) in patients aged 12 and older with specific mutations.

Key Takeaways

Due to the rising frequency of risk factors impacting liver fibrosis globally, the global liver fibrosis treatment market is projected to increase at a 10.8 percent CAGR during the forecast period.
Hepatotropic drugs accounted for a considerable market share in the liver fibrosis therapy industry, as they enable patients to get safe and effective treatment for fibrosis reduction.
Hospitals are anticipated to account for the majority of market share among end users during the forecast period since clinics are the leading alternative for patients with liver fibrosis.

Competitive Landscape

Key companies contributing in the global liver fibrosis treatment market are Johnson and Johnson, Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb, Merck & Co., Inc., Gilead Sciences, Inc., Pharmaxis Limited, FibroGen, Inc., Pfizer Inc., and Novartis AG.

Main points in Liver Fibrosis Treatment Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Liver Fibrosis Treatment Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Liver Fibrosis Treatment Industry Impact

Chapter 2 Global Liver Fibrosis Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Liver Fibrosis Treatment (Volume and Value) by Type
2.3 Global Liver Fibrosis Treatment (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Liver Fibrosis Treatment Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Liver Fibrosis Treatment Market Analysis
Chapter 6 East Asia Liver Fibrosis Treatment Market Analysis
Chapter 7 Europe Liver Fibrosis Treatment Market Analysis
Chapter 8 South Asia Liver Fibrosis Treatment Market Analysis
Chapter 9 Southeast Asia Liver Fibrosis Treatment Market Analysis
Chapter 10 Middle East Liver Fibrosis Treatment Market Analysis
Chapter 11 Africa Liver Fibrosis Treatment Market Analysis
Chapter 12 Oceania Liver Fibrosis Treatment Market Analysis
Chapter 13 South America Liver Fibrosis Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Liver Fibrosis Treatment Business
Chapter 15 Global Liver Fibrosis Treatment Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

Purchase The Report With Flat US $2000 Off: https://www.coherentmarketinsights.com/promo/buynow/2320

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com